Atrial fibrillation and anticoagulation therapy - Different race, different risk, and different management?-

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1314-1315

  Vivas, David ^a   Olmos, Carmen ^a   Vilacosta, Isidre ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CYTOCHROME P450 2C9; DABIGATRAN; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1;

ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; DISEASE REGISTRY; EDITORIAL; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; JAPANESE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOEMBOLISM;

ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD COAGULATION; DRUG MONITORING; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAPAN; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 79957863309     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0402     Document Type: Editorial

References (11)

1. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-618.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369 - 2429.
3. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 700-752.
4. Wolf PA, Abott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983.
5. Hart RG, Pearce LA, Aguilar MI. Metaanalysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
6. Shen AYJ, Yao JF, Brar SS, Jorgesen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with AF. J Am Coll Cardiol 2007; 50: 309-315.
7. Ogawa S, Aizawa Y, Atarashi H, Inoue H, Okumura K, Kamakura S. Guidelines for pharmacotherapy of atrial fibrillation. Circ J 2008; 72(Suppl IV): 1639-1658 (in Japanese).
8. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H for the J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-1333.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
11. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54: 1041-1057.